Market Cool On Shanghai Labway Clinical Laboratory Co., Ltd's (SZSE:301060) Revenues Pushing Shares 36% Lower

Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) shareholders won't be pleased to see that the share price has had a very rough month, dropping 36% and undoing the prior period's positive performance. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 59% loss during that time.

Although its price has dipped substantially, it's still not a stretch to say that Shanghai Labway Clinical Laboratory's price-to-sales (or "P/S") ratio of 1.5x right now seems quite "middle-of-the-road" compared to the Healthcare industry in China, where the median P/S ratio is around 1.7x. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.

See our latest analysis for Shanghai Labway Clinical Laboratory

How Shanghai Labway Clinical Laboratory Has Been Performing

As an illustration, revenue has deteriorated at Shanghai Labway Clinical Laboratory over the last year, which is not ideal at all. One possibility is that the P/S is moderate because investors think the company might still do enough to be in line with the broader industry in the near future. If you like the company, you'd at least be hoping this is the case so that you could potentially pick up some stock while it's not quite in favour.

Want the full picture on earnings, revenue and cash flow for the company? Then our free report on Shanghai Labway Clinical Laboratory will help you shine a light on its historical performance.

Is There Some Revenue Growth Forecasted For Shanghai Labway Clinical Laboratory?

There's an inherent assumption that a company should be matching the industry for P/S ratios like Shanghai Labway Clinical Laboratory's to be considered reasonable.

Retrospectively, the last year delivered a frustrating 35% decrease to the company's top line. Even so, admirably revenue has lifted 91% in aggregate from three years ago, notwithstanding the last 12 months. Accordingly, while they would have preferred to keep the run going, shareholders would definitely welcome the medium-term rates of revenue growth.

When compared to the industry's one-year growth forecast of 17%, the most recent medium-term revenue trajectory is noticeably more alluring

In light of this, it's curious that Shanghai Labway Clinical Laboratory's P/S sits in line with the majority of other companies. Apparently some shareholders believe the recent performance is at its limits and have been accepting lower selling prices.

What Does Shanghai Labway Clinical Laboratory's P/S Mean For Investors?

Following Shanghai Labway Clinical Laboratory's share price tumble, its P/S is just clinging on to the industry median P/S. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

We didn't quite envision Shanghai Labway Clinical Laboratory's P/S sitting in line with the wider industry, considering the revenue growth over the last three-year is higher than the current industry outlook. There could be some unobserved threats to revenue preventing the P/S ratio from matching this positive performance. It appears some are indeed anticipating revenue instability, because the persistence of these recent medium-term conditions would normally provide a boost to the share price.

Before you take the next step, you should know about the 4 warning signs for Shanghai Labway Clinical Laboratory that we have uncovered.

It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.